JP2021511830A5 - - Google Patents

Info

Publication number
JP2021511830A5
JP2021511830A5 JP2020561607A JP2020561607A JP2021511830A5 JP 2021511830 A5 JP2021511830 A5 JP 2021511830A5 JP 2020561607 A JP2020561607 A JP 2020561607A JP 2020561607 A JP2020561607 A JP 2020561607A JP 2021511830 A5 JP2021511830 A5 JP 2021511830A5
Authority
JP
Japan
Prior art keywords
amino acid
acid position
tyrosine
isolated
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511830A (ja
JP7399880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015204 external-priority patent/WO2019147973A1/en
Publication of JP2021511830A publication Critical patent/JP2021511830A/ja
Publication of JP2021511830A5 publication Critical patent/JP2021511830A5/ja
Priority to JP2023204313A priority Critical patent/JP7860946B2/ja
Application granted granted Critical
Publication of JP7399880B2 publication Critical patent/JP7399880B2/ja
Priority to JP2025179195A priority patent/JP2026021377A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561607A 2018-01-26 2019-01-25 FcRnへの増強された結合及び延長された半減期を有するFc変異体 Active JP7399880B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023204313A JP7860946B2 (ja) 2018-01-26 2023-12-04 FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP2025179195A JP2026021377A (ja) 2018-01-26 2025-10-24 FcRnへの増強された結合及び延長された半減期を有するFc変異体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
US62/622,468 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204313A Division JP7860946B2 (ja) 2018-01-26 2023-12-04 FcRnへの増強された結合及び延長された半減期を有するFc変異体

Publications (3)

Publication Number Publication Date
JP2021511830A JP2021511830A (ja) 2021-05-13
JP2021511830A5 true JP2021511830A5 (cg-RX-API-DMAC7.html) 2022-02-01
JP7399880B2 JP7399880B2 (ja) 2023-12-18

Family

ID=65520379

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020561607A Active JP7399880B2 (ja) 2018-01-26 2019-01-25 FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP2023204313A Active JP7860946B2 (ja) 2018-01-26 2023-12-04 FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP2025179195A Pending JP2026021377A (ja) 2018-01-26 2025-10-24 FcRnへの増強された結合及び延長された半減期を有するFc変異体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023204313A Active JP7860946B2 (ja) 2018-01-26 2023-12-04 FcRnへの増強された結合及び延長された半減期を有するFc変異体
JP2025179195A Pending JP2026021377A (ja) 2018-01-26 2025-10-24 FcRnへの増強された結合及び延長された半減期を有するFc変異体

Country Status (15)

Country Link
US (1) US20190263934A1 (cg-RX-API-DMAC7.html)
EP (1) EP3743441A1 (cg-RX-API-DMAC7.html)
JP (3) JP7399880B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250008975A (cg-RX-API-DMAC7.html)
CN (3) CN119350481A (cg-RX-API-DMAC7.html)
AU (2) AU2019212638B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015006A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089602A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010269A2 (cg-RX-API-DMAC7.html)
IL (2) IL318916A (cg-RX-API-DMAC7.html)
MX (2) MX2020007882A (cg-RX-API-DMAC7.html)
MY (1) MY203898A (cg-RX-API-DMAC7.html)
PH (1) PH12020551134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006905YA (cg-RX-API-DMAC7.html)
WO (1) WO2019147973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
CN114466663B (zh) * 2019-07-25 2026-01-02 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
JP7832123B2 (ja) * 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
WO2022090469A2 (en) * 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
WO2023021169A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US20240409618A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
JP2026513101A (ja) 2022-10-25 2026-04-23 アブリンクス エン.ヴェー. エフェクター機能が強化された糖鎖改変Fc変異ポリペプチド
TW202432602A (zh) 2022-12-05 2024-08-16 法商賽諾菲公司 運鐵蛋白受體結合蛋白
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
TW202619716A (zh) 2024-07-23 2026-05-16 法商賽諾菲公司 Cereblon連接酶調節劑與bcma nk細胞銜接子的組合療法
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8775090B2 (en) * 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) * 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CA3032820A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada

Similar Documents

Publication Publication Date Title
JP2024026255A5 (cg-RX-API-DMAC7.html)
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
CN110382529B (zh) 工程化的异源二聚体蛋白质
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
TWI320788B (en) Method for the purification of antibodies
JPWO2020116560A1 (ja) 抗体のFc領域改変体
US11945839B2 (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
CN111320693B (zh) 抗EphA4抗体
KR20120107140A (ko) 면역글로불린 용액 정제 방법
JP2020508968A (ja) プロテインlを用いたタンパク質精製
TW202233694A (zh) 雙特異性抗體
JP2025098167A5 (cg-RX-API-DMAC7.html)
JP7245373B2 (ja) 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法
JPWO2015050153A1 (ja) 免疫グロブリンG(IgG)のFc部分を有するタンパク質に対するアフィニティを有する複数のドメイン間をリンカーで結合させて成るタンパク質
JP2019030231A (ja) 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
TW202204423A (zh) 用於產生和純化多價免疫球蛋白單可變域的方法
CN110959012A (zh) 工程化表面电荷用于产生双特异性抗体的方法
JPWO2007063825A1 (ja) Cd166に対するモノクローナル抗体およびその産生方法
JP2024522092A5 (cg-RX-API-DMAC7.html)
JP2015003872A (ja) マウスIgGの精製方法
JP2015019615A (ja) プロテインgの細胞膜外ドメイン変異体の新規な改変型タンパク質
WO2021251438A1 (ja) エリスロポエチンポリペプチドを含む融合タンパク質
JP7839108B2 (ja) 筋萎縮性側索硬化症の治療用医薬組成物
NZ767453B2 (en) Fc variants with enhanced binding to fcrn and prolonged half-life